Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating expenses:
Research and development	$ 8,740	$ 5,478	$ 16,851	$ 9,751
Research and development, related party	29	315	178	703
General and administrative	4,932	2,914	9,804	5,132
Total operating expenses	13,701	8,707	26,833	15,586
Loss from operations	(13,701)	(8,707)	(26,833)	(15,586)
Other income (expense):
Change in fair value of redeemable convertible preferred stock tranche liability	0	0	0	(11,718)
Foreign currency loss	(1,042)	(12)	(1,199)	(16)
Other income, net	147	0	232	0
Total other income (expense)	(895)	(12)	(967)	(11,734)
Net loss	(14,596)	(8,719)	(27,800)	(27,320)
Accretion of redeemable convertible preferred stock to redemption value and cumulative preferred stock dividends	0	(2,141)	0	(3,226)
Net loss attributable to common stockholders	$ (14,596)	$ (10,860)	$ (27,800)	$ (30,546)
Net loss per share attributable to common stockholders, Basic	$ (0.56)	$ (3.11)	$ (1.06)	$ (8.80)
Net loss per share attributable to common stockholders, Diluted	$ (0.56)	$ (3.11)	$ (1.06)	$ (8.80)
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic	26,296,560	3,488,017	26,267,914	3,472,086
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, diluted	26,296,560	3,488,017	26,267,914	3,472,086
Comprehensive loss:
Net loss	$ (14,596)	$ (8,719)	$ (27,800)	$ (27,320)
Other comprehensive loss
Unrealized Gain (Loss) on Investments	(83)	0	(481)	0
Comprehensive loss	$ (14,679)	$ (8,719)	$ (28,281)	$ (27,320)